COMMUNIQUÉS West-GlobeNewswire

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
04/08/2026
New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategy JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE [...]
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
04/08/2026
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage [...]
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
04/08/2026
Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (" [...]
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
04/08/2026
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive [...]
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data [...]
Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases
04/08/2026
-- First‑in‑human trial of Oblenio’s sole asset, a CD19×BCMA×CD3 tri‑specific T‑cell engager, moves forward to rapidly generate broad proof of concept -- NANJING, China, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads [...]
Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.
04/08/2026
VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Tecan schedules conference call on August 11th to discuss half year 2026 financial results
04/08/2026
Männedorf, Switzerland, August 4, 2026 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2026 on Tuesday, August 11th, 2026, at 09:00 [...]
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
04/08/2026
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP by joint consensus [...]
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
04/08/2026
-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product [...]
NeurAxis Expands Payer Coverage with New Policies
04/08/2026
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial [...]
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
04/08/2026
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated [...]
Oblenio Announces First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases
04/08/2026
-- First-in-human trial of LBL-051 is enrolling patients with refractory autoimmune diseases to rapidly generate broad proof of concept -- Cambridge, Mass., August 4, 2026 - Oblenio Bio (“Oblenio” or “the Company”) [...]
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
04/08/2026
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
Transactions in connection with share buy-back program
04/08/2026
Company announcement no. 28 - 26 04 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
04/08/2026
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46 th Annual Growth Conference in Boston on August 12-13 [...]
AMSilk collaboration: Biotech silk protein yarns feature in Balenciaga 55th Couture Collection
04/08/2026
Haute Couture evening gown constructed using AMSilk-blend fabric Follows debut of AMSilk bioengineered silk protein yarns in Balenciaga Spring Collection 2026 NEURIED, Germany, Aug. 04, 2026 (GLOBE NEWSWIRE) -- AMSilk, [...]
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
04/08/2026
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an [...]

Pages